Ed Addison, is Chairman and CEO of Cloud Pharmaceuticals, a Research Triangle Park company from Duke University that applies AI to drug design, achieving unprecedented results. Cloud Pharmaceuticals has designed new drugs in development for cancer and other diseases. Ed is also Chairman of InferenSys, an AI machine learning company under wraps that applies a breakthrough machine learning method to big data, to launch in 2018. Ed is on the board of a number of companies deploying exponential technologies in life sciences, mobile apps and artificial intelligence, including Global Source Group, VoucherCart, Drug Logic and Parallel Medical Testing.
With a technical background in Artificial Intelligence, Ed is an established serial entrepreneur of disruptive ventures. Ed started 6 companies, funded 4 of them and exited 3. He has twice been named "Entrepreneur of the Year". He has advised 7 venture capital funds and over 20 early stage ventures. His expertise is in launching new technology ventures and new technology products.
Ed is an adjunct professor of engineering and entrepreneurship. He has taught Artificial Intelligence, Entrepreneurship, Engineering, Computer Science and Bioinformatics for several universities including NC State University, Stevens Institute of Technology and Johns Hopkins University. Ed holds a BSEE from Virginia Tech, two MS degrees from Hopkins, an MBA from Duke, and an 'online' law degree. He did a sabbatical year at MIT in AI.
In summary, Ed Addison is a multiple repeat early stage venture CEO with successful exits, and has twice been named "Entrepreneur of the Year". He advises, launches and raises capital for new disruptive high tech ventures and for companies launching new products. Ed is an experienced university professor and a frequent public speaker. In addition, Ed has deep technical skills in Artificial Intelligence, Cloud Computing and Bioinformatics.